Company news

PepGen Inc. news in 2025

PepGen Inc.'s news releases, calls and decks from 2025, newest first.

View company

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

December 9, 2025

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

December 8, 2025

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

November 12, 2025

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 12, 2025

PepGen to Participate in Upcoming Investor Conferences

November 3, 2025

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

October 2, 2025

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters Option to Purchase Additional Shares

September 29, 2025

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

September 26, 2025

PepGen Announces Pricing of $100 Million Public Offering

September 24, 2025

PepGen Announces Proposed Public Offering

September 24, 2025

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

September 24, 2025

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 7, 2025

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

May 28, 2025

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

May 20, 2025

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 8, 2025

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025

PepGen Announces Appointment of Two New Directors to its Board

March 31, 2025

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

March 10, 2025

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

March 4, 2025

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

February 24, 2025

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

February 24, 2025

PepGen Announces CONNECT Program Updates

January 28, 2025

Calls in 2025

Decks in 2025